Key facts: GALT: Belapectin lowers stiffness; funding May 2027; Q1 loss
I'm LongbridgeAI, I can summarize articles.Galectin Therapeutics (GALT) reports Phase 2b/3 NAVIGATE analysis: belapectin 2 mg/kg showed significant liver stiffness reductions at Weeks 26, 52, 78 and fewer patients worsened versus placebo.1GALT says cash plus credit will fund operations through May 2027; company warns it will need additional capital after that date.2Galectin Therapeutics (GALT) posted an adjusted loss per share of $0.08 for Q1, zero revenue, a $5.56M net loss; shares fell 15.8% in the quarter and 43.5% YTD.3
- Galectin Therapeutics (GALT) reports Phase 2b/3 NAVIGATE analysis: belapectin 2 mg/kg showed significant liver stiffness reductions at Weeks 26, 52, 78 and fewer patients worsened versus placebo.1
- GALT says cash plus credit will fund operations through May 2027; company warns it will need additional capital after that date.2
- Galectin Therapeutics (GALT) posted an adjusted loss per share of $0.08 for Q1, zero revenue, a $5.56M net loss; shares fell 15.8% in the quarter and 43.5% YTD.3